Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
NeuroPace Q1 2026 Earnings Call - Raised 2026 Revenue Guidance on Strong RNS Growth and IGE Progress
NeuroPace delivered a robust first quarter, posting $22.1 million in total revenue and raising its full-year 2026 guidance to $99–101 million. The beat reflects underlying RNS System growth of 21% to ...
- NeuroPace raised full-year 2026 revenue guidance to $99–101 million, up from $98–100 million, reflecting 21%–23% underlying RNS revenue growth.
- Q1 2026 total revenue reached $22.1 million, with RNS System revenue of $21.7 million, representing 19.5% year-over-year growth.
- The company reported all-time highs in active prescribers, accounts, and patient pipeline, signaling strong demand durability.
- +7 more takeaways
PagSeguro Digital Q1 2026 Earnings Call - Credit Surge and Operating Leverage Defy High Rates
PagSeguro Digital delivered a quarter defined by strategic pivots rather than top-line fireworks. Payment volumes sat flat, but the real story was the aggressive expansion of its credit book, which ju...
- Total Payment Volume (TPV) was flat year-over-year at BRL 128 billion, confirming a gradual reacceleration from prior quarters of contraction.
- Credit portfolio expanded 36% year-over-year to BRL 5 billion, with total loans reaching BRL 51 billion, driven by a 190% surge in working capital loans.
- Banking revenue grew 41% year-over-year, reflecting the successful pivot toward credit expansion and higher client transactionality.
- +9 more takeaways
Oklo Inc" Q1 2026 Earnings Call - Vertically Integrated Nuclear Platform Accelerates with 229-Day Reactor Build and DOE-to-NRC Licensing Pathway
Oklo Inc. moved decisively from strategy to execution in the first quarter of 2026, demonstrating that advanced nuclear deployment can outpace historical norms. The company completed construction of i...
- Oklo completed construction of the Groves Isotope Test Reactor in 229 days, proving that nuclear assets can be built at a pace that defies industry norms and validating the company’s speed thesis.
- The company ended Q1 2026 with $2.5 billion in cash and marketable securities, including $1.2 billion raised through a completed ATM program, providing ample runway for deployment across power, fuel, and isotopes.
- Oklo is executing a dual regulatory strategy, using DOE authorizations to advance early assets like Aurora-INL while preparing for NRC Part 57 fleet licensing, which targets 6-12 month review cycles for standardized reactors.
- +7 more takeaways
BODi Q1 2026 Earnings Call - Nutrition-First Pivot and Retail Expansion Drive Profitability
BODi delivered its third consecutive quarter of profitability, with Q1 2026 revenue of $54.3 million beating guidance. The company is executing a strategic pivot away from its legacy MLM model toward ...
- Q1 2026 revenue of $54.3 million exceeded the high end of guidance, marking continued momentum in the company's transformation.
- BODi posted its third consecutive quarter of profitability, with net income of $2.3 million and operating income of $3.1 million.
- Adjusted EBITDA reached $8.0 million, the tenth consecutive quarter of positive results, up from $3.7 million in the prior year.
- +7 more takeaways
SenesTech Q1 2026 Earnings Call - Record Subscription Growth and Amazon Transition Drive Revenue Momentum
SenesTech reported a pivotal quarter under new CEO Michael Edell, marking a decisive shift toward direct-to-consumer sales and recurring revenue. The company brought its Amazon operations in-house, a ...
- New CEO Michael Edell is executing a strategic pivot from B2B-heavy to a direct-to-consumer first model, emphasizing data, control, and recurring revenue.
- Q1 revenue grew a modest 2% to $493,000, but the composition shifted dramatically toward higher-margin, direct channels.
- Direct-to-consumer revenue surged 42% to a record $194,000, driven by the successful transition of Amazon operations from third-party to in-house management.
- +7 more takeaways
Coincheck Group Q1 FY2027 Earnings Call - New CEO Unveils Platform Strategy Amid KDDI Partnership and Revenue Shift
Coincheck Group reported a fourth quarter fiscal 2026 total revenue increase of 4% year-over-year to JPY 119.7 billion, driven by institutional and counterparty transaction revenue. However, adjusted ...
- New CEO Pascal St-Jean announced a strategic shift from a holding company structure to a unified crypto financial services platform targeting both retail and institutional clients.
- The platform strategy is built on three pillars: Japanese retail dominance, institutional expansion via 3iQ acquisition, and on-chain innovation including Web3 wallets and tokenization.
- Strategic partnership with KDDI includes a 14.9% equity investment and a business alliance for mutual customer referrals, providing access to millions of potential retail users in Japan.
- +9 more takeaways
Lumexa Imaging Q1 2026 Earnings Call - Advanced Modalities Surge as Weather and Seasonality Temporarily Dampen EBITDA
Lumexa Imaging delivered Q1 2026 results that aligned with management’s expectations, highlighting a strategic pivot toward high-margin advanced imaging modalities that drove a 7% year-over-year growt...
- Consolidated revenues grew 3% year-over-year to $253 million, while system-wide revenue growth reached 4%, with two-thirds driven by volume and one-third by rate increases.
- Advanced modality volumes surged 7% year-over-year, with PET leading at 23.1% growth and MRI rising 8.2%, signaling a successful strategic shift toward higher-reimbursement services.
- Adjusted EBITDA remained flat at $51.2 million, impacted by approximately $4 million in weather-related volume softness and enhanced seasonality that suppressed early-year scan volumes.
- +7 more takeaways
Capricor Therapeutics Q1 2026 Earnings Call - Lawsuit Against NS Pharma Signals Push for Independent DMD Launch
Capricor Therapeutics is positioning for an independent commercial launch of deramiocel for Duchenne muscular dystrophy after filing a lawsuit to rescind its distribution agreement with NS Pharma. CEO...
- Capricor filed a lawsuit on May 7, 2026, to rescind its U.S. distribution agreement with NS Pharma and Nippon Shinyaku, seeking a preliminary injunction to distribute deramiocel independently.
- The BLA for deramiocel to treat Duchenne muscular dystrophy is under active FDA review with a PDUFA target date of August 22, 2026.
- NS Pharma refused to renegotiate the pricing structure, which Capricor states would create hundreds of thousands of dollars in reimbursement shortfalls per dose for providers.
- +7 more takeaways
Astronics Q1 2026 Earnings Call - Record Bookings and Backlog Drive Raised Full-Year Outlook
Astronics delivered a record-breaking start to 2026, with Q1 revenue of $231 million and bookings of $290 million, pushing the backlog to an all-time high of $734 million. The company raised its full-...
- Record Q1 Bookings and Backlog: Bookings hit a record $290 million with a 1.26 book-to-bill ratio, pushing the backlog to an all-time high of $734 million, signaling strong near-term demand.
- Raised Full-Year Guidance: Management increased 2026 revenue guidance to $970 million–$1 billion, up from the previous range of $950 million–$990 million, reflecting organic growth momentum.
- Strong Q1 Revenue and Earnings: Revenue reached $231 million (high end of guidance), up 12% year-over-year. Adjusted EPS rose 34% to $0.59, and adjusted net income grew 32.6% to $22.5 million.
- +7 more takeaways
Spectral AI Q1 2026 Earnings Call - DeepView FDA Clearance Nears, $31.7M BARDA Award Drives 2027 Revenue
Spectral AI reported a solid start to 2026, driven by a $31.7 million acceleration in BARDA funding and continued progress on its DeepView burn assessment system. The company delivered a prototype for...
- DeepView FDA De Novo Application Status: Management remains confident in receiving FDA clearance before the end of Q2 2026, following an active dialogue and additional information requests since the June 2025 submission.
- Commercialization Timeline: The company aims to commercialize the DeepView system for the burn indication by the end of 2026, with initial sales targeted for late 2026 in international markets (U.K., Australia, GCC) pending expanded UKCA labeling.
- $31.7 Million BARDA Award: Spectral AI secured $31.7 million in advanced funding from BARDA in March 2026, which includes a no-cost extension and acceleration of Phase II. This funding supports feature design and procurement of up to 30 devices for burn centers and trauma departments.
- +9 more takeaways